Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:0080199 |
| Name | colorectal carcinoma |
| Definition | A colorectal cancer that arises from the colon or rectum and invades through the muscularis mucosa into the submucosa. |
| Source | DiseaseOntology.org |
| Alt Ids | |
| Path | disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer intestinal cancer large intestine cancer colorectal cancer colorectal carcinoma |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|---|---|---|---|
| EML4 - ALK | Crizotinib | colorectal carcinoma | predicted - sensitive | detail... |
| EML4 - ALK | Lorlatinib | colorectal carcinoma | predicted - sensitive | detail... |
| MSH6 F1088Lfs*5 MSH6 Y1256* MSH6 A1320Sfs*5 | Nivolumab | colorectal carcinoma | predicted - sensitive | detail... |
| BRAF V600E | Mirdametinib + Palbociclib | colorectal carcinoma | no benefit | detail... |
| BRAF V600E | Gedatolisib + Palbociclib | colorectal carcinoma | sensitive | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02611024 | Phase Ib/II | Irinotecan + Lurbinectedin | Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors | Completed | USA | ITA | FRA | ESP | DEU | CHE | 0 |
| NCT02977156 | Phase I | Ipilimumab + JX-594 | Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors. (ISI-JX) | Completed | FRA | 0 |
| NCT03264664 | Phase I | E7386 | Study of E7386 in Participants With Selected Advanced Neoplasms | Active, not recruiting | USA | GBR | 0 |
| NCT03287427 | Phase I | TetMYB + Tislelizumab | MYPHISMO: MYB and PD-1 Immunotherapies Against Multiple Oncologies Trial (MYPHISMO) | Completed | AUS | 0 |
| NCT03401294 | Phase II | Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | Conversion From Unresectable To Resectable Metastatic Colorectal Cancer. (CONVERSION) | Recruiting | CAN | 0 |
| NCT03428958 | Phase I | A Safety Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment | Completed | USA | GBR | FRA | 0 | |
| NCT03517488 | Phase I | XmAb20717 | A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) | Completed | USA | 0 |
| NCT03752398 | Phase I | Izuralimab | A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3) | Completed | USA | 0 |
| NCT03849469 | Phase I | Pembrolizumab + XmAb22841 XmAb22841 | A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4) | Completed | USA | 0 |
| NCT03957096 | Phase I | SGN-CD47M | A Safety Study of SGN-CD47M in Patients With Solid Tumors | Terminated | USA | 0 |
| NCT04060407 | Phase Ib/II | CD24Fc + Ipilimumab + Nivolumab | CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI) (CINDI) | Withdrawn | USA | 0 |
| NCT04096638 | Phase I | Nivolumab + SB 11285 SB 11285 | Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors | Completed | USA | 0 |
| NCT04672434 | Phase I | Sym021 + Sym024 Sym024 | Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies | Completed | USA | CAN | 0 |
| NCT04735796 | Phase I | LM-102 | Study of LM-102 in Subjects in Advanced Tumors | Terminated | USA | 0 |
| NCT04752215 | Phase I | BI 765049 + Ezabenlimab BI 765049 | A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface | Completed | USA | CAN | 0 |
| NCT04793958 | Phase III | Adagrasib + Cetuximab Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin | Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) | Active, not recruiting | USA | ROU | POL | NLD | ITA | IRL | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG | 12 |
| NCT04975256 | Phase I | Adagrasib + BI 1701963 | Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14) | Terminated | USA | 0 |
| NCT05001516 | Phase Ib/II | TPX-4589 | Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors | Completed | USA | 0 |
| NCT05217446 | Phase II | Pembrolizumab Cetuximab + Encorafenib + Pembrolizumab | A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer (SEAMARK) | Active, not recruiting | USA | SVK | POL | NOR | NLD | ITA | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BEL | AUS | 0 |
| NCT05378425 | Phase I | NTX-1088 NTX-1088 + Pembrolizumab | A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab | Recruiting | USA | POL | ISR | 0 |
| NCT05625412 | Phase I | CC-90001 + Nivolumab Capecitabine + CC-90001 CC-90001 CC-90001 + Docetaxel | A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors | Completed | USA | ITA | FRA | ESP | CAN | AUS | ARG | 2 |
| NCT05700656 | Phase Ib/II | Capecitabine + Galunisertib | Galunisertib Combined With Capecitabine in Advanced CRC With PM | Recruiting | NLD | 0 |
| NCT05786924 | Phase Ib/II | BDTX-4933 + Fluorouracil + Irinotecan + Leucovorin + Panitumumab BDTX-4933 + Cetuximab + Fluorouracil + Irinotecan + Leucovorin BDTX-4933 BDTX-4933 + Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab BDTX-4933 + Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin BDTX-4933 + Gemcitabine + Nab-paclitaxel | Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies | Recruiting | USA | 0 |
| NCT05958199 | Phase I | NPX267 | Treatment With NPX267 for Subjects With Solid Tumors Known to Express HHLA-2 | Suspended | USA | 0 |
| NCT06105021 | Phase Ib/II | AFNT-211 | Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor | Active, not recruiting | USA | 0 |
| NCT06120075 | Phase I | AB801 AB801 + Docetaxel AB801 + Docetaxel + Zimberelimab | A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies (ARC-27) | Recruiting | USA | 0 |
| NCT06216561 | Phase I | CEND-1 | Intraperitoneal LSTA1 in CRS-HIPEC | Withdrawn | USA | 0 |
| NCT06240728 | Phase I | NPX887 | A Study of NPX887 for Participants With Solid Tumors Known to Express HHLA2/B7-H7 | Recruiting | USA | 1 |
| NCT06399757 | Phase Ib/II | APL-5125 | A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors | Recruiting | USA | 0 |
| NCT06444815 | Phase I | VET3-TGI Pembrolizumab + VET3-TGI | A Study of VET3-TGI in Patients With Solid Tumors (STEALTH-001) | Recruiting | USA | 0 |
| NCT06462183 | Phase I | RGT-61159 | Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC) | Recruiting | USA | CAN | 0 |
| NCT06723236 | Phase I | MGC028 | A Study of MGC028 in Participants with Advanced Solid Tumors | Recruiting | USA | 0 |
| NCT06760819 | Phase II | Sevabertinib | A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) (panSOHO) | Recruiting | USA | ITA | FRA | ESP | DNK | CHE | CAN | AUS | 3 |
| NCT06840119 | Phase Ib/II | IMC-R117C | Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers | Recruiting | NLD | ITA | ESP | DEU | BEL | AUS | 0 |
| NCT06882746 | Phase I | BI 765049 | A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas | Recruiting | USA | 0 |
| NCT06939283 | Phase Ib/II | WTX-330 | A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma | Recruiting | USA | 0 |
| NCT07107230 | Phase I | JNJ-95437446 | A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors | Recruiting | USA | 0 |